health
April 2, 2026
Russia begins first clinical trial of new cancer vaccine for melanoma
Russia has started clinical use of a personalized cancer vaccine for a melanoma patient, with early results expected in three months
TL;DR
- A Russian melanoma patient received the first personalized cancer vaccine, Neooncovac.
- The vaccine analyzes a patient's tumor genome to create a customized treatment that trains the immune system to attack cancer cells.
- The 60-year-old patient is reported to be doing well with no adverse reactions.
- Neooncovac is an mRNA-based vaccine and is part of a new approach to cancer treatment.
- Preclinical trials showed significant tumor disappearance and a high response rate for metastases.
- The vaccine is expected to be available for free treatment under Russia's national health insurance system.
- The Gamaleya Center is also developing treatments for pancreatic, kidney, and lung cancer.
Continue reading the original article